发布求助
文献互助 智能选刊 最新文献

Current opinion in investigational drugs (London, England : 2000)最新文献

筛选
英文 中文
Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials. 创伤后应激障碍的药物治疗：来自随机对照试验的证据。
Current opinion in investigational drugs (London, England : 2000) Pub Date : 2009-01-01
Gregory M Sullivan, Yuval Neria
{"title":"Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials.","authors":"Gregory M Sullivan, Yuval Neria","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This review discusses evidence-based pharmacotherapies for post-traumatic stress disorder (PTSD). The epidemiology of PTSD and its phenomenological characteristics are summarized. Focus is placed on the major classes of drugs for which at least a minimum of evidence-based outcome data are available from randomized controlled trials (RCTs). Drugs for the total symptom constellation of the disorder, specific PTSD symptoms, such as nightmares, and prevention of PTSD development post-trauma, are discussed. Where appropriate, RCT methodological problems that limit the conclusions drawn are discussed. In addition, recommendations for research to fill critical gaps in the knowledge of PTSD treatment are offered.</p>","PeriodicalId":101403,"journal":{"name":"Current opinion in investigational drugs (London, England : 2000)","volume":"10 1","pages":"35-45"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The manipulation of cation-chloride co-transporters as a novel means to treat persistent pain, epilepsy and other neurological disorders. 操纵阳离子-氯化物共转运体作为治疗持续性疼痛、癫痫和其他神经系统疾病的新方法。
Current opinion in investigational drugs (London, England : 2000) Pub Date : 2009-01-01
Jeffrey A M Coull, Martin Gagnon
{"title":"The manipulation of cation-chloride co-transporters as a novel means to treat persistent pain, epilepsy and other neurological disorders.","authors":"Jeffrey A M Coull, Martin Gagnon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Existing members of the anti-epileptic drug (AED) class often fail to provide meaningful symptom relief to patients experiencing persistent pain, epilepsy and other neurological disorders, and can evoke substantial adverse events. In an effort to improve treatment options, much attention has turned to novel mechanisms that may represent points of therapeutic intervention. Among these mechanisms are the cation-chloride co-transporters (CCCs), the dysfunction of which has been linked to aberrant chloride homeostasis in neurons of the CNS, and resulting disorders including persistent pain and epilepsy. This review examines the literature linking CCCs to neurological disease, and discusses their considerable potential as the basis for novel therapeutic strategies.</p>","PeriodicalId":101403,"journal":{"name":"Current opinion in investigational drugs (London, England : 2000)","volume":"10 1","pages":"56-61"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138816195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
hIL-13-PE38QQR. NeoPharm. hIL-13-PE38QQR。NeoPharm.
Current opinion in investigational drugs (London, England : 2000) Pub Date : 2001-09-01
S Barth
{"title":"hIL-13-PE38QQR. NeoPharm.","authors":"S Barth","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>NeoPharm, under license from the NIH and the FDA, is developing a chimeric human IL-13 fused in frame to a genetically engineered truncated Pseudomonas exotoxin (PE38QQR) molecule, for its potential as an antitumor agent [266296], [281418], [290480]. NeoPharm filed an IND in 1999 for renal cell carcinoma (RCC) and glioma [319690], [325001]; an additional IND was filed in March 2000 for the treatment of glioblastoma. In December 2000, NeoPharm initiated phase I/II trials of IL-13-PE38QQR involving patients with refractory glioblastoma multiforme. This trial was being conducted by the New Approaches to Brain Tumor Therapy, a research consortium sponsored by the NCI. At that time, the first patient with brain cancer had completed treatment with IL-13-PE38QQR [393197]. In October 1999, NeoPharm initiated phase I trials of hIL-13-PE38QQR for the treatment of patients with RCC [343878]. In February 2000, Dirks & Co estimated the potential US market for hIL-13-PE38QQR to be $5.8 billion [414515].</p>","PeriodicalId":101403,"journal":{"name":"Current opinion in investigational drugs (London, England : 2000)","volume":"2 9","pages":"1309-13"},"PeriodicalIF":0.0,"publicationDate":"2001-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138816196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信